03.09.2018 • NewsBoehringer IngelheimDede Willams

Boehringer plans Solids Launch Unit

Boehringer plans Solids Launch Unit (c) Boehringer
Boehringer plans Solids Launch Unit (c) Boehringer

Boehringer Ingelheim has broken ground for a new €85 million facility at its headquarters in Ingelheim, Germany. The Solids Launch plant, slated to start up in 2020 and employ 75 people, will focus on developing and manufacturing new tablet-form pharmaceuticals.

The drugmaker said its “new vision” for production of solid medications will see the headquarters site develop and manufacture more complex tablets for global launches. At the same time, it is continuously moving production of older, easier-to-manufacture products to other sites within its global manufacturing network.

When the new facility at Ingelheim is up and running, production of less complex drugs will be relocated from Germany to less expensive countries such as Mexico and Greece.

The Solids Launch plant will incorporate new manufacturing methods, including continuous production and a contained production train to handle higher potent compounds, Boehringer said. It also will have a flexible layout that allows for rearrangements of rooms and equipment to speed production starts

At Ingelheim, said Stefan Rinn, country manager for Germany, the company is “thoroughly committed to investing in technologies and processes with high added value. This is why it is  establishing the site as a centerpiece for global market launches of pharmaceutical innovation.

Boehringer is also incorporating the €34 million “diabetes factory” it completed last year into its new launch strategy.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.